Nexeon has an extensive intellectual property portfolio covering a broad range of innovative ideas for minimally invasive therapies.

These emerging product categories include nanotechnology-based devices, embolic protection systems, local drug/biologic delivery systems and cell delivery/regenerative therapy devices in various stages of development.

Nanotechnology-Based Transcatheter Designs

Nexeon believes that the application of nanotechnology to interventional devices will change the rules under which device designers operate, allowing them to implement improvements not previously deemed possible. Nexeon and Unidym, Inc. are working together to incorporate carbon nanotube technology in medical devices for the treatment of cardiovascular disease. This collaboration positions Nexeon for leadership in this next wave of device innovations.

Embolic Protection Systems

Nexeon is developing proprietary anatomy-specific combination embolic protection and stent delivery systems for endovascular procedures. These products provide efficient embolic particle retrieval while improving ease of use, redefining the standard of care for these important procedures.

Local Drug/Biologic Delivery Systems

Nexeon has strong intellectual property and initial prototypes for devices designed to provide localized, temporary delivery of drugs, genes, or therapeutic agents to target organs. The Nexeon local drug delivery product line could change the way solid organ tumors, chronic critical limb ischemia and many other conditions are treated.

Cell Delivery/Regenerative Therapies

Nexeon has developed proprietary technology for effective delivery of stem cells or biologics to target end-organ sites in order to treat conditions such as chronic congestive heart failure, chronic critical limb ischemia and acute myocardial infarction.

CAUTION – Investigational device. Limited by Federal (U.S.) law to investigational use.